83 results about "Adenosine monophosphate" patented technology

The invention relates to a saccharomyces cerevisiae strain for efficiently synthesizing cordycepin as well as a construction method and application of the saccharomyces cerevisiae strain, and belongs to the technical field of microbial genetic engineering. The construction method provided by the invention comprises the following steps: carrying out multi-copy genome integrated expression on heterologous codon optimized 2 '-carbonyl-3'-deoxyadenosine reductase genes and 3 '-adenosine monophosphate phosphohydrolase genes, so as to increase the dosage of key enzymes; and supplementing the defective gene of the engineering strain to obtain the saccharomyces cerevisiae strain B5U3 with high yield of cordycepin. According to the obtained saccharomyces cerevisiae strain for efficiently synthesizing the cordycepin, the cordycepin yield reaches 2.92 g / L after shake flask fermentation, the cordycepin yield reaches 7.5 g / L after fermentation in a fermentation tank, and a foundation is laid for safer and more reliable industrial production of the cordycepin.

The invention relates to the technical field of microbial genetic engineering, in particular to a method for improving cordycepin synthesized by saccharomyces cerevisiae and saccharomyces cerevisiae engineering bacteria. According to the invention, codon-optimized 2 '-carbonyl-3'-deoxyadenosine reductase gene and 3 '-adenosine monophosphate phosphohydrolase gene from cordyceps militaris are expressed by using plasmids, and then the plasmids are transformed into host cells to obtain the saccharomyces cerevisiae engineering bacteria. And inoculating a seed solution obtained by seed culture of the activated saccharomyces cerevisiae engineering bacteria into a fermentation culture medium containing a metabolic effector, and carrying out fermentation culture to synthesize cordycepin. Metabolic effectors (Cu < 2 + >, Fe < 2 + >, Mg < 2 + >, Zn < 2 + >, citric acid, cysteine, aspartic acid, glycine, VB1 and tea polyphenol) are added into a fermentation culture medium strain, and the variety and concentration of the metabolic effectors are optimized, so that the yield and synthesis efficiency of cordycepin are remarkably improved. By using the combination of the strain obtained by the invention and the optimal effector, the yield of cordycepin in a fermentation tank reaches 2.9 g / L.

The invention discloses a 3 '-phosphoadenosine-5'-phosphoryl sulfate synthetase mutant and an application of the 3 '-phosphoadenosine-5'-phosphoryl sulfate synthetase mutant. Compared with a wild enzyme amino acid sequence as shown in SEQ ID NO.1, the amino acid sequence of the 3 '-adenosine-5'-phosphoryl sulfate synthetase mutant has one or two mutations in the 101 site, the 207 site and the 560 site; preferably, phenylalanine at the 101 site is mutated into tryptophan; cysteine at the 207th site is mutated into glycine; phenylalanine at the 560th site is mutated into tryptophan. The invention also provides a synthesis method and application of the 3 '-adenosine-5'-phosphoryl sulfuric acid. The APS intermediate product inhibition effect of hPAPSS1 is relieved through a point mutation technology, the substrate affinity of hPAPSS1 to ATP is improved, and a mutant enzyme with a high PAPS conversion rate is obtained; and the bifunctional enzyme hPAPSS1 is synthesized by heterologous expression of PAPS in escherichia coli, so that the acquisition of the enzyme is simplified, and the synthesis efficiency of PAPS is improved.

The invention relates to the technical field of biological medicine, in particular to a novel polypeptide and application thereof in medicine for treating cardiovascular diseases. The polypeptide has a unique amino acid sequence, and is composed of an amino acid sequence of SEQ. NO: 1: Leu-Asn-Pro-Thr-Glu (LNPTG), an amino acid sequence of SEQ. NO: 2: Val-His-Met-Arg-Tyr (VHMRY), and the like. The polypeptide has a unique amino acid sequence, and provides a new way for the treatment of cardiovascular diseases by adjusting the activity of AMPK and improving the cardiovascular function.

The invention relates to the technical field of drugs for gene therapy, in particular to application of CAP-Gly functional peptide in preparation of drugs for treating fatty liver. The invention provides application of a CAP-Gly functional peptide or a reagent for improving the expression quantity of the CAP-Gly functional peptide in preparation of a medicine for treating fatty liver. The amino acid sequence of the CAP-Gly functional peptide is shown as SEQ ID NO.23. The invention further provides a preparation method of the CAP-Gly functional peptide. The invention finds that the overexpression of the KIF13B protein or the CAP-Gly functional peptide thereof in mice can effectively reduce lipid accumulation in liver cells and increase phosphorylation of protein kinase alpha activated by adenosine monophosphate, and provides a new target and a new strategy for precise treatment of patients with fatty liver (especially metabolism-related fatty liver diseases) clinically.

The invention provides a metabonomics-based preeclampsia risk assessment prediction model construction method, a prediction model, application of metabolites, a metabolite detection kit, a prediction product, a prediction system and related application thereof. Specifically, clinical indexes and metabolite data of a pregnant woman serve as input, whether the pregnant woman suffers from preeclampsia or not serves as output, model construction is conducted through a machine learning method, and a preeclampsia risk assessment and prediction model is obtained. The metabolite is selected from at least one of 4-hydroxyphenyllactic acid, homovanillic acid, ornithine, sarcosine, adenosine monophosphate and 3-methylbutyryl carnitine. According to the invention, not only are six metabolite markers strongly associated with preeclampsia found, but also effective prediction of early preeclampsia and late preeclampsia is realized by establishing a prediction model, and the method has extremely high clinical value.

A method and composition for enhancing adenosine monophosphate-activated protein kinase (AMPK) activity and improving mitochondrial-related oxidative metabolism parameters in motor and sedentary mammals by oral intake of low doses of D-ribose, thereby promoting overall metabolic health in mammals.

This application discloses a cyclic GMP-AMP synthase mutant. Compared to the wild-type cyclic GMP-AMP synthase shown in SEQ ID NO.1, the amino acid sequence of the cyclic GMP-AMP synthase mutant has any one of the following mutations: L377M or H437T / S434T. Specifically, the amino acid sequence of the L377M mutated cyclic GMP-AMP synthase mutant is shown in SEQ ID NO.4, and the amino acid sequence of the H437T / S434T mutated cyclic GMP-AMP synthase mutant is shown in SEQ ID NO.9. The cGAS mutant of this application exhibits four times the activity of the wild-type. The preparation method uses readily available and economical raw materials, is simple to operate, environmentally friendly, and pollution-free, with high synthesis efficiency, making it suitable for industrial development.

The invention discloses an AMP sulfating enzyme mutant for producing adenosine phosphoryl sulfuric acid and application, and belongs to the technical field of biological engineering. According to the invention, AMP is used as a raw material, and AMP sulfating enzymes BtaAPSST M2 and PcAPSK are used for biosynthesis of PAPS. Under the catalysis of 10 g / L of BtaAPSST M2 wet thallus and 20 g / L of PcAPSK wet thallus, the conversion rate of PAPS is 70.59%. Compared with the existing ATP sulfating enzyme capable of catalyzing ATP to generate APS, the ATP sulfating enzyme disclosed by the invention is lower in cost and equivalent in conversion rate. Wherein the PAPS yield of the BtaAPSST M2 is two times that of a wild enzyme, and the industrial process of producing the PAPS by a microbial synthesis method is accelerated.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for distinguishing hypertrophic cardiomyopathy and left ventricular hypertrophy and application. The application analyzes the metabolome of hypertrophic cardiomyopathy (HCM) patients, left ventricular hypertrophy (LVH) patients caused by non-hypertrophic cardiomyopathy and healthy people, finds that carnitine C16:2, carnitine C14:0, carnitine C16:0, carnitine C18:0 and carnitine C18:1 are differentially expressed in HCM patients and LVH patients, pyridoxine phosphate, ito acid, adenosine monophosphate, adenosine diphosphate and adenosine triphosphate are differentially expressed in HCM patients and healthy people, lysine base, methyl glutamic acid, acetyl proline, malate semialdehyde and citramalate are differentially expressed in LVH patients and healthy people, and ROC curve analysis shows excellent prediction effect, strong specificity and high sensitivity.

Disclosed in the invention are a type of compounds having activity of activating 5′-adenosine monophosphate-activated protein kinase (AMPK), a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for reducing fatty acid synthesis, for inhibiting triglyceride and cholesterol synthesis, for preventing and / or treating obesity and type II diabetes, for preventing and / or treating tumor, for preventing and / or treating Parkinson's disease, for preventing and / or treating Alzheimer's disease or for prolonging the lifespan of mammals:

The present invention relates to compounds of formulae I to V and of formulae Ib to Vb, their use as activators of the long cyclic nucleotide phosphodiesterase-4 (PDE4) enzyme (isoform), and to the use of these compounds in methods of treating or preventing conditions requiring reduction of a second messenger response mediated by cyclic adenosine 3 ', 5'-monophosphate (cAMP).

The invention relates to the technical field of enzymes, in particular to a BsBacD enzyme mutant, an enzyme composition and a preparation method of tyrosine dipeptide. The method comprises the following steps: rationally designing BsBacD enzyme, replacing ADP (adenosine diphosphate or salt thereof) with relatively cheap ATP (adenosine triphosphate or salt thereof) or relatively cheap AMP (adenosine monophosphate or salt thereof), and introducing polyphosphate kinase ChPPK2 capable of regenerating ATP by taking AMP as a substrate to synthesize tyrosine dipeptide; parameters such as reaction pH, magnesium chloride concentration, substrate tyrosine concentration and the like are optimized, and a low-cost and efficient enzymatic synthesis process of three tyrosine dipeptides such as propyl tyrosine dipeptide, glycyl tyrosine dipeptide and sericin tyrosine dipeptide is developed.

A type lll-B system from Haliangium ochraceum contains two caspase-like proteases, SAVED-CHAT and PCaspase (prokaryotic caspase). Cyclic tri-adenosine monophosphate (AMP)-induced oligomerization of SAVED-CHAT activates proteolytic activity of the CHAT domains, which specifically cleave and activate PCaspase. Subsequently, activated PCaspase cleaves a multitude of proteins, which results in a strong interference phenotype in vivo in Escherichia coli. This provides for a CRISPR-Cas-based method of detecting a target RNA, whereby detection signalling is triggered via a cascade of caspase-associated proteolytic activities. Polynucleotides, plasmids, vectors and nucleoprotein complexes comprising nucleic acids encoding the components of the system are provided.

The present application belongs to the technical field of biological fermentation and discloses a process for the production of L-histidine by biological fermentation. It comprises the following steps: inoculating a seed solution of Escherichia coli into a fermenter containing a fermentation medium at a culture temperature of 35-37°C, maintaining the reducing sugar content at 46 g / L by adding a glucose solution containing adenosine monophosphate in fed-batch increments, stopping the addition of the glucose solution 4 hours before the end of fermentation, maintaining the pH in the fermenter at 6.9-7.1 by adding ammonia solution in fed-batch increments, and adding an antifoaming agent to control foaming, with the fermentation time being 40-50 hours, thereby obtaining an L-histidine fermentation solution.The process according to the present application exhibits high fermentation efficiency and low production costs and is suitable for industrial production.

The invention provides a method for simultaneously determining various flavor nucleotides in a livestock and poultry meat product and application, and the method comprises the following steps: freeze-drying the livestock and poultry meat product, and then preparing the freeze-dried livestock and poultry meat product into a test solution; measuring the contents of CMP (cytidylic acid), ATP (adenosine triphosphate), GMP (guanine monophosphate), IMP (inosinic acid), ADP (adenosine diphosphate), Hy (hypoxanthine), AMP (adenosine monophosphate) and IN (inosine) in the test solution by adopting HPLC (high performance liquid chromatography); in HPLC, a mobile phase A is a phosphate buffer solution with the volume concentration of 95%, a mobile phase B is methanol with the volume concentration of 5%, gradient elution is carried out, and the gradient elution condition is 0-11 min, 99% phosphate buffer solution and 1% methanol; when 12 min, 80% phosphate buffer solution and 20% methanol are added, and the conditions are maintained for 6-7 min; the phosphate buffer solution is heated to 99% within 2 minutes, and then the temperature is kept for 8-10 minutes.

Cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) synthase (cGAS) is an enzyme sensor of double-stranded DNA (dsDNA) that serves to trigger activation of the cGAS-stimulator of interferon genes (STING) pathway. The inhibition of cGAS with Cladophorol A is described herein.

The invention discloses an application of lactobacillus delbrueckii subsp. Lactis ABSN20244504 and a metagen thereof in preparation of a product for inhibiting skin light injury, and relates to the technical field of microorganisms, the preservation number of the strain is CGMCC No.34743, and the strain is separated from traditional fermented yak yoghourt in the Alba plateau in Sichuan of China and has good capability of tolerating artificial gastric acid and cholate in vitro. The invention also discloses an application of the strain and the inactivated metagen thereof in preparation of a product for inhibiting skin light injury. Animal experiments show that the mouse skin injury induced by ultraviolet B can be obviously relieved whether the viable bacteria of the strain are orally taken or locally smeared with inactivated postbiotics of the strain, and the action mechanism of the strain is related to oxidative stress relieving, inflammatory reaction inhibiting, AMPK (adenosine monophosphate kinase) adjusting and other related signal channels. The invention provides a new strain resource and an application strategy for developing a novel oral probiotic preparation and an external cosmetic for preventing and repairing skin light injury.

The invention relates to the technical field of biological medicines, and particularly discloses application of adenosine monophosphate in preparation of a medicine for treating osteoarthritis. Cell tests show that the adenosine monophosphate solution has an inhibition effect on cartilage cell activity; animal model tests show that the adenosine monophosphate normal saline solution can remarkably relieve the cartilage injury degree of osteoarthritis mice and relieve osteoarthritis, and a new way is provided for improvement of osteoarthritis conditions. The chemical structural formula of adenosine monophosphate is shown in the specification.

The present invention belongs to the technical field of preparing functional materials for molecular recognition, adsorption and separation, and discloses a method for preparing a hydrophilic dual-receptor MOFs nanosheet surface imprinted adsorbent and its application in the selective separation of adenosine monophosphate. The present invention targets the structural characteristics of a typical nucleoside compound adenosine monophosphate (AMP) molecule, designs and synthesizes Zr-MOFs nanosheets coordinated with its specific metal ion as a matrix material, and uses 5-(2-methoxyvinyl)-2′-deoxyuridine (AcrU) as a functional monomer that undergoes specific base complementary pairing. The arrangement and orientation of the template molecules are precisely fixed through an ordered assembly strategy. Finally, the large number of double bonds modified on the surface of the Zr-MOFs nanosheets and a hydrophilic cross-linking agent are utilized to photoinitiate the construction of a stable hydrophilic dual-receptor MOFs nanosheet surface imprinted adsorbent (D-MIPs), thereby enhancing the recognition and separation effect of nucleoside compounds and achieving the selective separation and enrichment of nucleoside compounds such as AMP in biological samples such as urine and blood.

The present invention relates to a blood treatment device configured to dephosphorylate extracellular adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP) and / or lipopolysaccharide (LPS) in the blood of a patient in need thereof in an extracorporeal blood circuit, wherein the device comprises a matrix on which alkaline phosphatase (AP) is immobilized. The present invention also relates to an extracorporeal blood circuit comprising a blood treatment device of the present invention and to the use of the blood treatment device as a medicament or a method for treating an infection, preferably a blood or systemic infection such as sepsis, and / or for treating sepsis-related acute kidney injury (AKI).

The application provides a uridine monophosphate specific glycoside hydrolase and application thereof in biosynthetic synthesis of pseudouridine. Nmygdh The function of the gene is verified by in-vitro enzyme activity experiment Nmygdh The recombinant protein has broad-spectrum and high-efficiency catalytic activity, and can efficiently catalyze the hydrolysis of glycosidic bonds in various nucleotides, such as uridine monophosphate (UMP), guanosine monophosphate (GMP), adenosine monophosphate (AMP) and cytidine monophosphate (CMP), and the activity of uridine monophosphate is the strongest. The application uses the protein to efficiently hydrolyze uridine monophosphate to obtain two substrates of pseudouridine, i.e. uracil and 5'-phosphoribose, and realizes the atom-economical and efficient biosynthetic synthesis of pseudouridine by combining the cascade reaction of pseudouridine glycosidase EcPsuG and dephosphorylase EcYjjG.

The invention belongs to the technical field of biological detection and analysis, and particularly relates to an adenosine phosphate photoaffinity probe as well as a preparation method and application thereof. The probe comprises an AMP-N (adenosine monophosphate-N) photoaffinity probe, an ADP-N (adenosine monophosphate-N) photoaffinity probe and an ATP-N (adenosine monophosphate-N) photoaffinity probe, the phosphoric acid part of adenosine monophosphate is modified with a photoaffinity group diaziridine with a small volume and alkynyl capable of carrying out a biological orthogonal reaction, and a connecting bond capable of cracking under an acidic condition is designed between adenosine monophosphate and a photoreactive group. The probe is high in stability and good in marking efficiency, can specifically mark the adenosine phosphate binding protein and identify the binding site of the adenosine phosphate binding protein, is suitable for screening, functional research and affinity analysis of the adenosine phosphate binding protein and discovery and verification of related drug targets, and has a wide application prospect.

The application discloses a cyclic GMP-AMP synthetase mutant and a method for preparing 2',3'-cyclic guanosine monophosphate-adenosine monophosphate by using the cyclic GMP-AMP synthetase mutant, wherein the amino acid sequence of the cyclic GMP-AMP synthetase mutant has any one of the following mutations: P361A, L377M, K432R, S221Y / F357L / I496V, S221L / Y248F / K432H / S434T, F357L / P361A / L377M / S434T, F357L / P361A / S434T / H437T or H437T / S434T, compared with a wild type as shown in SEQ ID NO. 1. The activity of the cGAS mutant of the application can reach 4 times of the wild type, raw materials of the preparation method are economical and easy to obtain, the operation is simple, green, environment-friendly, pollution-free, the synthesis efficiency is high, and industrial development is easy.

This method and composition involves oral administration of a low dose of D-ribose to enhance adenosine monophosphate-activated protein kinase (AMPK) activity in both exercising and sedentary mammals, improve mitochondrial-related oxidative metabolic parameters, and thereby promote overall metabolic health in mammals.

This invention provides a kit for the simultaneous detection of nine flavor nucleotides in livestock and poultry products. The flavor nucleotides are cytidine monophosphate, uridine monophosphate, guanylic acid, inosine monophosphate, adenosine monophosphate, hypoxanthine, inosine, adenosine diphosphate, and adenosine triphosphate. The kit includes: a high-concentration extraction reagent, a standard curve solution, a high-concentration phosphate buffer solution, pH adjustment solution A, and pH adjustment solution B. The high-concentration extraction reagent is perchloric acid; the standard curve solution is a mixed solution of the nine flavor nucleotides; the high-concentration phosphate buffer solution is a solution of potassium dihydrogen phosphate and dipotassium hydrogen phosphate; pH adjustment solution A is sodium hydroxide; and pH adjustment solution B is phosphate. This invention also provides a method for the simultaneous detection of the nine flavor nucleotides using the above kit. This invention enables the simultaneous determination of the content of nine flavor nucleotides in livestock and poultry products. The method is simple, rapid, accurate, and sensitive, and can be used for batch determination, showing good prospects for practical application.

The present disclosure relates to methods and compositions for editing an AMPK polynucleotide encoding an AMPK protein. The disclosure also relates to methods and compositions for modulating activity of an AMPK protein, for promoting activation of an AMPK protein, for repairing function of a pathogenic AMPK protein, and methods for regulating energy homeostasis and / or for treating or preventing an AMPK-associated disease or condition in a subject.

The present invention discloses a steel bar rust inhibitor for use in complex chloride environments, as well as its preparation and use methods. The steel bar rust inhibitor comprises a solvent and a solute dissolved therein, wherein the solvent is hydrolase-free double-distilled water with a pH greater than 6.0; the solute comprises, by mass percentage, 80%-90% DAP dry powder and 10%-20% PVA powder; wherein the DAP is prepared by grafting adenosine monophosphate, adenosine diphosphate, and adenosine triphosphate onto a nucleoside phosphorous acid activated intermediate. Compared with existing rust inhibitors, the present invention utilizes a more simplified synthesis method, which, while ensuring significant rust inhibition, avoids the limitations of the use environment and the agglomeration phenomenon caused by excessive molecular weight.

The present application relates to the technical field of enzyme, in particular to a mutant of BsBacD enzyme, an enzyme composition and a preparation method of tyrosine dipeptide. The present application firstly rationally designs the BsBacD enzyme, then replaces ADP (adenosine diphosphate or its salt) with relatively cheap ATP (adenosine triphosphate or its salt) or even cheaper AMP (adenosine monophosphate or its salt), and introduces polyphosphate kinase ChPPK2 which can regenerate ATP with AMP as a substrate to synthesize tyrosine dipeptide, and optimizes reaction pH, magnesium chloride concentration and substrate tyrosine concentration and other parameters, and develops a low-cost and high-efficiency enzyme synthesis process of three kinds of tyrosine dipeptides, such as propyl tyrosine dipeptide, glycosyl tyrosine dipeptide and silk tyrosine dipeptide.

The invention provides a construction method of a multi-parameter pre-eclampsia risk assessment prediction model, a prediction model, a prediction product, a prediction system and related applications thereof. Specifically, six metabolic markers including 4-hydroxyphenyllactic acid, homovanillic acid, ornithine, sarcosine, adenosine monophosphate and 3-methylbutyryl carnitine and two preeclampsia-related protein markers IGFBP1 and PLGF are measured, the blood pressure of both arms of an individual is measured, the average arterial pressure is calculated, clinical information of a maternal body is combined, and the blood pressure of both arms of the individual is calculated. A metabolism and protein marker multi-index combined prediction model for the onset risk of preeclampsia of pregnancy 12-17 + 6 weeks is established. The effect of the random forest model for screening early-onset and late-onset eclampsia is better than that of using a single protein or metabolite marker or other metabolism and protein marker combined models, so that the work of predicting the preeclampsia occurrence risk in 12-17 + 6 weeks of pregnancy is realized, and clinical doctors are guided to carry out advanced intervention.